Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$5.147M
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
109.04%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Book Value
Cash
Q4 2024
P/E
-1.533
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Revenue $0.00 $0.00 $0.00 $328.8K $410.0K $211.8K $228.3K $1.272M $758.7K $372.1K $545.5K $290.0K $700.0K $850.0K $0.00 $0.00
YoY Change -100.0% -19.8% 93.53% -7.2% -82.05% 67.62% 103.88% -31.78% 88.09% -58.57% -17.65%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Revenue $0.00 $0.00 $0.00 $328.8K $410.0K $211.8K $228.3K $1.272M $758.7K $372.1K $545.5K $290.0K $700.0K $850.0K $0.00 $0.00
Cost Of Revenue $0.00 $17.60K $100.0K $133.3K $250.0K $818.6K $580.8K $469.1K $57.35K $440.0K $1.010M $390.0K
Gross Profit $0.00 $311.2K $310.0K $78.53K -$21.76K $453.1K $177.9K -$97.02K $488.1K -$150.0K -$310.0K $460.0K
Gross Profit Margin 94.65% 75.61% 37.07% -9.53% 35.63% 23.44% -26.07% 89.49% -51.72% -44.29% 54.12%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Selling, General & Admin $4.428M $5.035M $5.734M $3.380M $2.050M $2.760M $2.940M $3.320M $3.230M $2.870M $1.770M $4.430M $3.610M $1.070M $70.00K $20.00K
YoY Change -12.06% -12.19% 69.65% 64.88% -25.72% -6.12% -11.45% 2.79% 12.54% 62.15% -60.05% 22.71% 237.38% 1428.57% 250.0%
% of Gross Profit 1086.12% 661.29% 3514.45% 732.69% 1815.98% 362.62% 232.61%
Research & Development $2.882M $4.795M $13.34M $17.95M $3.329M $1.100M $2.087M $1.973M $1.729M $1.029M $2.459M $2.019M $1.830M $830.0K $350.0K
YoY Change -39.89% -64.05% -25.7% 439.04% 202.68% -47.3% 5.78% 14.11% 67.99% -58.13% 21.82% 10.3% 120.48% 137.14%
% of Gross Profit 1069.88% 354.84% 2657.99% 381.67% 578.8% 413.54% 76.09%
Depreciation & Amortization $186.0K $4.328B $6.991B $8.323B $9.602B $0.00 $188.4K $179.3K $149.6K $159.5K $158.3K $124.8K $110.0K $90.00K $10.00K
YoY Change -100.0% -38.09% -16.0% -13.32% -100.0% 5.05% 19.9% -6.24% 0.76% 26.82% 13.48% 22.22% 800.0%
% of Gross Profit 3085475.58% 0.0% 239.86% 33.01% 89.69% 25.57% 2.17%
Operating Expenses $2.882M $4.795M $13.34M $17.95M $3.329M $3.140M $5.290M $5.453M $6.180M $5.097M $6.091M $4.393M $6.370M $4.520M $1.430M $70.00K $20.00K
YoY Change -39.89% -64.05% -25.7% 439.04% 6.03% -40.64% -2.98% -11.77% 21.24% -16.31% 38.63% -31.03% 40.93% 216.08% 1942.86% 250.0%
Operating Profit -$7.015M -$9.223M -$18.37M -$23.68M -$6.401M -$2.830M -$5.078M -$5.225M -$4.908M -$4.339M -$5.719M -$3.905M -$6.520M -$4.830M -$970.0K
YoY Change -23.94% -49.8% -22.43% 269.97% 126.18% -44.27% -2.8% 6.44% 13.13% -24.13% 46.43% -40.1% 34.99% 397.94%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Interest Expense $268.1K $42.41K -$1.860K $40.00K $60.00K $40.00K $190.0K $100.0K -$600.0K -$160.0K -$90.00K $10.00K $1.240M $150.0K $0.00 $0.00
YoY Change 532.16% -2380.11% -104.65% -33.33% 50.0% -78.95% 90.0% -116.67% 275.0% 77.78% -1000.0% -99.19% 726.67%
% of Operating Profit
Other Income/Expense, Net $845.5K $849.1K $780.3K $10.34M $37.41K $40.10K $194.7K -$110.5K $1.532M -$2.694M -$10.65M $1.310M
YoY Change -0.43% 8.83% -92.45% 27535.47% -79.4% -276.16% -107.21% -156.88% -74.7% -912.75%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Pretax Income -$6.169M -$8.374M -$17.55M -$13.34M -$6.363M -$2.780M -$4.307M -$4.540M -$4.001M -$3.258M -$4.183M -$2.082M -$5.200M -$3.600M -$590.0K -$60.00K -$20.00K
YoY Change -26.33% -52.28% 31.52% 109.67% 128.9% -35.45% -5.14% 13.47% 22.8% -22.11% 100.89% -59.95% 44.44% 510.17% 883.33% 200.0%
Income Tax $800.00 $800.00 $800.00 $800.00 $800.00 $800.00 $800.00 $7.200K $36.80K $27.20K $800.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.200M -$8.374M -$17.55M -$13.34M -$6.360M -$2.780M -$5.039M -$5.031M -$5.026M -$2.843M -$8.440M -$14.50M -$5.200M -$3.600M -$590.0K -$60.00K -$20.00K
YoY Change -25.96% -52.28% 31.52% 109.8% 128.78% -44.83% 0.17% 0.09% 76.79% -66.31% -41.78% 178.76% 44.44% 510.17% 883.33% 200.0%
Net Earnings / Revenue -1934.3% -678.05% -2378.56% -2203.65% -395.23% -374.73% -2267.88% -2657.49% -1793.1% -514.29% -69.41%
Basic Earnings Per Share -$1.93 -$2.93 -$0.57 -$0.36 -$1.11 -$2.81
Diluted Earnings Per Share -$2.93 -$1.053M -$1.105M -$738.7K -$551.6K -$10.50M -$20.96M -$0.57 -$0.36 -$1.11 -$2.81 -$52.00M -$40.00M -$14.75M -$6.000M -$4.550M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Cash & Short-Term Investments $5.361M $7.091M $7.839M $7.210M $5.030M $10.30M $6.570M $11.41M $8.970M $13.89M $7.860M $1.000M $4.150M $2.000M $200.0K $50.00K
YoY Change -24.39% -9.55% 8.73% 43.34% -51.17% 56.77% -42.42% 27.2% -35.42% 76.72% 686.0% -75.9% 107.5% 900.0% 300.0%
Cash & Equivalents $5.361M $7.091M $7.839M $7.210M $5.030M $510.0K $4.570M $7.420M $3.960M $13.43M $7.860M $320.0K $920.0K $2.000M $200.0K $0.00
Short-Term Investments $6.080M $1.990M $3.990M $5.020M $460.0K $0.00
Other Short-Term Assets $448.9K $745.5K $948.7K $800.0K $400.0K $90.00K $120.0K $360.0K $180.0K $130.0K $90.00K $30.00K $40.00K $20.00K $0.00 $10.00K
YoY Change -39.79% -21.41% 18.58% 100.0% 344.44% -25.0% -66.67% 100.0% 38.46% 44.44% 200.0% -25.0% 100.0% -100.0%
Inventory $220.0K $70.00K $250.0K $560.0K
Prepaid Expenses
Receivables $626.5K $1.255M $3.303M $90.00K $220.0K $40.00K $0.00 $90.00K $160.0K $60.00K $20.00K $20.00K $40.00K $570.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $160.0K $0.00 $0.00 $0.00
Total Short-Term Assets $6.437M $9.092M $12.09M $8.100M $5.640M $10.66M $6.760M $12.10M $9.870M $14.07M $8.130M $1.050M $4.220M $2.590M $200.0K $50.00K
YoY Change -29.2% -24.8% 49.27% 43.62% -47.09% 57.69% -44.13% 22.59% -29.85% 73.06% 674.29% -75.12% 62.93% 1195.0% 300.0%
Property, Plant & Equipment $100.1K $31.16K $111.6K $170.0K $70.00K $1.060M $880.0K $760.0K $500.0K $390.0K $250.0K $330.0K $340.0K $90.00K
YoY Change 221.18% -72.07% -34.38% 142.86% -93.4% 20.45% 15.79% 52.0% 28.21% 56.0% -24.24% -2.94% 277.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $50.00K $70.00K $70.00K
YoY Change -28.57% 0.0%
Other Assets $173.5K $171.5K $20.00K $20.00K $20.00K $20.00K $20.00K $20.00K $20.00K $20.00K $10.00K $0.00 $30.00K
YoY Change 1.18% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Total Long-Term Assets $2.454M $2.484M $2.494M $2.660M $80.00K $1.120M $960.0K $840.0K $520.0K $400.0K $380.0K $490.0K $530.0K $300.0K $0.00 $40.00K
YoY Change -1.22% -0.41% -6.24% 3225.0% -92.86% 16.67% 14.29% 61.54% 30.0% 5.26% -22.45% -7.55% 76.67% -100.0%
Total Assets $8.890M $11.58M $14.58M $10.76M $5.720M $11.78M $7.720M $12.94M $10.39M $14.47M $8.510M $1.540M $4.750M $2.890M $200.0K $90.00K
YoY Change
Accounts Payable $1.747M $2.122M $1.380M $1.460M $460.0K $490.0K $320.0K $620.0K $660.0K $530.0K $420.0K $430.0K $160.0K $420.0K $0.00 $10.00K
YoY Change -17.66% 53.77% -5.49% 217.39% -6.12% 53.13% -48.39% -6.06% 24.53% 26.19% -2.33% 168.75% -61.9% -100.0%
Accrued Expenses $74.71K $18.98K $78.81K $70.00K
YoY Change 293.62% -75.92% 12.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.822M $2.141M $1.459M $1.530M $460.0K $490.0K $320.0K $620.0K $2.380M $1.420M $3.870M $560.0K $160.0K $420.0K $0.00 $10.00K
YoY Change -14.9% 46.76% -4.66% 232.61% -6.12% 53.13% -48.39% -73.95% 67.61% -63.31% 591.07% 250.0% -61.9% -100.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.77K $43.66K $67.71K $120.0K $0.00 $5.350M $6.840M $130.0K $1.530M
YoY Change -54.72% -35.52% -43.58% -100.0% -21.78% 5161.54% -91.5%
Total Long-Term Liabilities $19.77K $43.66K $67.71K $120.0K $0.00 $0.00 $0.00 $0.00 $0.00 $5.350M $6.840M $130.0K $1.530M $0.00 $0.00 $0.00
YoY Change -54.72% -35.52% -43.58% -100.0% -21.78% 5161.54% -91.5%
Total Liabilities $1.842M $2.184M $1.526M $1.650M $460.0K $490.0K $320.0K $620.0K $2.380M $6.770M $10.71M $690.0K $1.690M $420.0K $0.00 $10.00K
YoY Change -15.69% 43.11% -7.49% 258.7% -6.12% 53.13% -48.39% -73.95% -64.84% -36.79% 1452.17% -59.17% 302.38% -100.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Basic Shares Outstanding 3.197M 2.859M 8.826M shares 7.957M shares 7.583M shares 5.161M shares
Diluted Shares Outstanding 8.826M shares 7.957M shares 7.583M shares 5.161M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $7.8912 Million

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. The company is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. The company has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The company is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.

Industry: Pharmaceutical Preparations Peers: NYMOX PHARMACEUTICAL CORP Xenon Pharmaceuticals Inc.